Diversa Signs Agreement with GlaxoSmithKline to Advance Development of a Novel Anti-Infective Compound
Under the terms of this agreement, Diversa will have the primary responsibility to develop the chemistry processes required to advance the compound into clinical development. Upon achievement of specific performance criteria by Diversa, GSK will have the option to further develop this compound and obtain exclusive worldwide commercialization rights in exchange for milestone payments, option and license fees, and royalties to Diversa. If GSK decides not to exercise this option, then Diversa will obtain development and commercialization rights to the compound in exchange for royalties to GSK.
"We look forward to working on this important anti-infective compound, which is complementary with our anti-infective focus and our strategy of pursuing therapeutics to treat serious, hospital-based infections," said Dr. Jay M. Short, Diversa's President and Chief Executive Officer.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.